Intercept

ICPT NASDAQ
64.00
-0.64
-0.99%
盘后: 64.00 0 0.00% 17:58 08/16 EDT
开盘
65.16
昨收
64.64
最高
65.86
最低
63.03
成交量
45.18万
成交均量(3M)
60.36万
52周最高
133.74
52周最低
58.21
换手率
1.38%
市值
20.93亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Intercept ICPT股票价格,Intercept股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company's product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The Company's product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). In addition to OCA, it is developing other bile acid analog compounds targeting FXR and a second dedicated bile acid receptor called TGR5, which is a target of interest for the treatment of type 2 diabetes and other gastrointestinal indications. The Company is also developing other products INT-767 for the treatment of fibrosis and INT-777 for the treatment of type 2 diabetes.
展开 >

最近浏览

名称
价格
涨跌幅